I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $293.7M |
||||||
Company | Location | Date | Amt. (M) | Details |
||
Atrium Biotechnologies Inc. | Quebec City, Quebec | 9/6 | C$10 (US$6.75) | Aeterna Laboratories Inc. (AELA) announced that SGF Soquia Inc., Fonds de solidarite FTQ and Fonds d'investissement bio-alimentaire acquired 1M shares in its privately held subsidiary, Atrium |
||
BioWisdom Ltd. | Cambridge, UK | 9/11 | US$2.8 | Company completed a first round of financing with MB Venture Capital for US$2.8M |
||
Dynavax Technologies Corp. | Berkeley, Calif. | 9/26 | $22.6 | Company completed a $22.6M private placement of preferred stock; investors included Alta Partners, Axiom Venture Partners, BA Venture Partners, Biotechvest LP, Forward Ventures, InterWest Partner, Sanderling, bioMerieux Alliance SA, China Development Industrial Bank, JAFCO, Phillips Capital Management and Finedix BV, as well as various individuals |
||
Eos Biotechnology Inc. | South San Francisco | 9/28 | $27.5 | Eos completed a $27.5M private placement of preferred stock; investors included Affymetrix, Biogen, Medarex, U.S. Bancorp Piper Jaffray, Robertson Stephens and other existing investors |
||
ExonHit Therapeutics | Paris | 9/5 | EUR13.9 (US$12.4) | ExonHit raised EUR13.9M in private equity with investors AGF Private Equity, BNP Private Equity, Oxford Bioscience, Sofinnova Partners and CDC Innovation |
||
FibroGen Inc. | South San Francisco | 9/28 | $56.5 | Company completed a $56.5M private placement of convertible preferred stock; investors included a syndicate representing Finland, Japan, Taiwan and current stockholders and were led by Franklin Templeton Investments and America Express Financial Advisors |
||
Hypnion Inc. | Worcester, Mass. | 9/26 | $10.4 | Hypnion raised $10.4M in private equity financing led by Oxford Bioscience Partners investors also included AGTC Funds and GIMV |
||
Immunicon Corp. | Huntingdon Valley, Pa. | 9/11 | $21.75 | Immunicon completed a $21.75M private offering of convertible preferred equity; Canaan Partners and Foundation Medical Partners led the financing, which included MDS Capital Corp., TL Ventures, Anthem Capital, Johnston Associates, Johnson & Johnson Development Corp., LHC Corp. and MedCapital |
||
Ingenium Pharmaceuticals | Martinsried, Germany | 9/11 | EUR50 (US$43.1) | Ingenium completed a EUR50M private placement; the investment was led by Schroder Ventures and Sofinnova Partners, and included Polaris Venture Partners, Lehman Brothers, Index Ventures, Deutsche Bank, Sal. Oppenheim, IKB, New Medical Technologies, tbg, Bayern Kapital, TVM and Alpinvest |
||
NeuralStem Biopharmaceuticals Ltd. | College Park, Md. | 9/27 | $.5 | Company announced a $500,000 investment from the state of Maryland's Enterprise Investment Fund |
||
Neurotrophic Bioscience Inc. | Toronto | 9/12 | C$6 (US$4) | Company completed a second round of financing from its existing investors, Business Development Bank of Canada, GeneChem Technologies Venture Fund L.P. and Sofinov |
||
Novazyme Pharmaceuticals Inc. | Oklahoma City | 9/18 | $8 | Novazyme completed an $8M equity financing through the private placement of Series A preferred stock; the placement was co-led by Catalyst Health & Technology Partners, HealthCare Ventures and Perseus-Soros Biopharmaceutical Fund |
||
Panacea Pharmaceuticals Inc. | Rockville, Md. | 9/27 | ND | Company announced the completion of its Series A round of financing, which was over-subscribed |
||
PTC Therapeutics Inc. | South Plainfield, N.J. | 9/26 | $15 | Company received $15M in a financing led by Vulcan Ventures Inc., CSFB Private Equity and New Medical Technologies |
||
Senomyx Inc. | La Jolla, Calif. | 9/14 | $10 | Senomyx completed a $10M private placement of Series B preferred stock; the financing was led by Alejandro Zaffaroni and included the Baker Tisch Investments LLC, Bay City Capital, Domain Associates, Prospect Ventures, Kingsbury Capital Partners and Rho Management |
||
Signature BioScience | Burlingame, Calif. | 9/6 | $17 | The financing was led by Atlas Venture of Boston, and included CIBC Capital Partners Coral Ventures, Prospect Venture Partners and Abingworth Management |
||
Structural GenomiX | San Diego | 9/20 | $45 | Structural GenomiX completed a $45M round of private equity financing led by BA Venture Partners; other investors included Amerindo, MDS Health Ventures, Orbimed Advisors, Vector Fund Management, Atlas Ventures, Apple Tree Partners, The Sprout Group, Index Ventures and Vulcan Northwest; S.G. Cowen served as placement agent |
||
TransMolecular Inc. | Birmingham, Ala. | 9/14 | $9 | TransMolecular completed a $9M Series B financing led by TVM Techno Venture Management GmbH; the financing included Tullis-Dickerson & Co. Inc., President Life Sciences Co. Ltd., Pacific Horizon Partners III, Portrush Group and Suttle Brothers Investments |
||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $10M | ||||||
Company (Symbol)# | Partner (Symbol; Country) | Amt. (M) | Triggering Event | Details (Date) |
||
Arena Pharmaceuticals Inc. (ARNA) | Eli Lilly & Co. | ND | Research milestone | Arena received its first research milestone payment from Lilly related to Lilly's acceptance of CART-activated versions of three G protein-coupled receptors (9/25) |
||
Compugen Ltd. (CGEN) | Pfizer Global Research and Development (NYSE:PFE) | ND | Development milestone | Compugen identified predicted genes through clustering and assembly of genomic DNA and cDNA sequences as part of a 1998 multi-year agreement with Warner-Lambert Co., which has been acquired by Pfizer Inc. (9/13) |
||
ImmunoGen Inc. (IMGN) | SmithKline Beecham | $2 | Development milestone | Company received a $2M payment from SmithKline for entering a second Phase I/II trial for huC242-DM1/SB-408075 (9/21) |
||
Interneuron Pharmaceuticals Inc. (IPIC) | Pfizer Inc. | $3 | Development milestone | Interneuron announced it would receive a $3M payment from Pfizer for the initiation of clinical trials checking the safety and efficacy of pagoclone for use in panic disorder (9/12) |
||
Iomai Corp.* | Mitsubishi Corp. (Japan) | US$2 | Equity investment | A wholly-owned subsidiary of Mitsubishi made the investment, the first direct investment by Japanese interests in Iomai (9/5) |
||
Genomica Corp.* | Applied Biosystems (formerly P.E. Biosystems [NYSE:PEB]) | $3 | Equity investment | Applied Biosystems made the equity investment in Genomica at the same time the two companies formed a technology license agreement (9/6) |
||
MorphoSys AG (Germany; Neuer Markt:MOR) | GPC Biotech AG (Neuer Markt:GPC) | ND | Development milestone | MorphoSys received a milestone payment for developing high-affinity antibodies in its immunology collaboration with GPC (9/25) |
||
Notes: |
||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||||
*Denotes privately held company. |
||||||